MedTrace Logo

Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis

NCT05513014 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1518

Last updated 2022-11-08

No results posted yet for this study

Summary

The study was conducted to describe the demographics, disease characteristics, disease severity, comorbidities and patient reported outcomes at baseline and follow-up periods among adult patients diagnosed with PsO in CorEvitas' PsO Registry under routine medical care initiating secukinumab (SEC).

Conditions

Interventions

DRUG

Secukinumab

Patients with Psoriasis who initiated Secukinumab

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-21
Primary Completion
2021-08-31
Completion
2021-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05513014 on ClinicalTrials.gov